Hypoxia-inducible factor-1α and ischemia-modified albumin levels in intensive care COVID-19 Patients

Yücel, Kamile; Gurbuz, Ali Fuat

doi:10.1515/hmbci-2022-0024

Cited by 4 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent studies, higher IMA levels were found in COVID-19 patients compared to control groups [ 24 , 25 , 26 ]. In Yucel et al’s study with 70 patients in the ICU, the serum IMA levels were determined to be significantly higher compared to the healthy control group [ 27 ]. However, in the study of Altıntas et al, no significant difference was determined in the serum IMA levels between the COVID-19 and the control groups [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

“…There are few studies in the literature comparing the presence of additional disease and serum IMA levels in COVID-19 patients. In Yucel et al’s study, it was found that the levels of IMA were higher in COVID-19 patients with at least one chronic disease than in those without any such diseases [ 27 ]. In the study of Ogihara et al, in which they looked at the impact of obesity on disease severity in patients with COVID-19, a higher prevalence of HT and DM was found in the obesity group compared to the non-obese [ 35 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Analysis of Ischemia-Modified Albumin (IMA) and Coagulation Parameters in Patients with SARS-CoV-2 Pneumonia

Gökmen

Şener

Bayrak

et al. 2023

JCM

View full text Add to dashboard Cite

Background: Coronavirus disease 2019 (COVID-19) is a systemic disease which causes an increased inclination to thrombosis by leading to coagulation system activation and endothelial dysfunction. Our objective in this study is to determine whether ischemia-modified albumin (IMA) can be used as a new marker in patients with COVID-19 for evaluating the increased coagulation risk, pneumonic infiltration, and thus, prognosis. Methods: Our study included 59 patients with COVID-19 compatible pneumonic infiltration on lung computed tomography (CT) who applied to and were hospitalized in the Internal Diseases Outpatient Clinic, then followed up and treated, as well as 29 healthy individuals with a negative COVID-19 rRT-PCR test without any additional disease. Hemogram, coagulation, routine biochemistry, and serum IMA activity parameters were studied. Results: In our study, the higher serum IMA level in COVID-19 patients with pneumonic infiltration compared to that of the healthy control group was found to be statistically significant. No significant correlation was found between the serum IMA levels and the coagulation and inflammation parameters in the 59 COVID-19 patients included. Conclusions: Serum IMA levels in COVID-19 patients with pneumonic infiltration on CT were found to be higher than in the control group. Examination of biochemical parameters, especially thrombotic parameters that affect prognosis such as IMA, can be a guide in estimating pneumonic infiltration.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Analysis of Ischemia-Modified Albumin (IMA) and Coagulation Parameters in Patients with SARS-CoV-2 Pneumonia

Gökmen

Şener

Bayrak

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…They observed that higher levels of IMA, a marker of oxidative damage, were associated with the severity of pulmonary involvement, and suggested that IMA may be a predictive factor of pulmonary involvement. Yucel et al [21] determined that IMA levels in COVID-19 patients in the intensive care unit were relatively higher compared to healthy controls. They also observed that IMA levels in COVID-19 patients with chronic disease were significantly higher compared to those without and stated that the presence of chronic disease may lead to an increase in IMA levels by aggravating oxidative stress.…”

Section: Discussionmentioning

confidence: 99%

The relationship between ischemia-modified albumin/albumin ratio levels and disease severity in COVID-19 patients

aksit

2023

Int J Med Biochem

View full text Add to dashboard Cite

The relationship between ischemia-modified albumin/ albumin ratio levels and disease severity in COVID-19 patients I n December 2019, the Coronavirus disease (COVID-19), caused by a virus called SARS-CoV-2, was detected in Wuhan, China. COVID-19 quickly spread throughout China and the whole world [1]. The World Health Organization (WHO) declared COVID-19 a pandemic on March 11, 2020 due to its uncontrollable spread [2]. The COVID-19 pandemic has been responsible for more than 649,000,000 cases and 6,600,000 deaths as of December 2022 [3]. COVID-19 can be asymptomatic or symptomatic. The symptomatic form may have a dis-ease spectrum ranging from mild upper respiratory tract disease to severe interstitial pneumonia, resulting in respiratory failure and even death [4,5]. Therefore, identifying potentially critically ill patients is extremely important. With the early detection of these patients and appropriate treatment options, both hospitalization and mortality rates can be reduced. In many studies, a relationship between the inflammatory state called cytokine storm and the deterioration of the clinical condition of COVID-19 patients has been reported [4,6,7]. It is

show abstract

“…In healthy people, free oxygen radicals produced by metabolism are removed by the antioxidant system, the body's defence mechanism. However, in COVID-19 patients, this radical damage is increased due to hypoxia, ischaemia, comorbidities, medical treatment and viral load [4][5][6] . Due to the widespread damage to cells and tissues caused by COVID-19 infection, it is difficult to identify of a specific laboratory parameter that can assess the severity of the disease and its impact on mortality.…”

Section: Introductionmentioning

confidence: 99%

Plasma kallistatin levels in patients with COVID-19

YUCEL,

YILDIZ,

GURBUZ

2023

Cukurova Medical Journal

Self Cite

View full text Add to dashboard Cite

Purpose: The aim of this study was to evaluate kallistatin levels in patients diagnosed with COVID-19 and compare them with healthy controls. Materials and Methods: A total of 40 patients diagnosed with COVID-19, and 45 healthy controls were included in the study. The patient group was divided into 2 groups: patients treated in the service (n:20) and patients treated in the intensive care unit (n:20). Kallistatin levels were measured using the ELISA method. Results: There was a significant difference in kallistatin levels between the patient group (n:40) and the control group (n:45). There was no significant difference in kallistatin between COVID-19 patients treated in the service and those treated in the intensive care unit. We found that the AUC for kallistatin was 0.856 in the ROC analysis performed between the patient and control groups. When comparing service and ICU patients in terms of laboratory parameters, there was a significant difference between the groups due to elevated potassium, AST, creatinine, ferritin, HGB and LDH in ICU patients. Conclusion: As a result, kallistatin levels were significantly higher in the patient group than in the control group. Comprehensive studies with more patients are needed to understand whether kallistatin is elevated in COVID-19 patients due to the effects of COVID-19 or to eliminate oxidative stress.

show abstract

Hypoxia-inducible factor-1α and ischemia-modified albumin levels in intensive care COVID-19 Patients

Cited by 4 publications

References 33 publications

Analysis of Ischemia-Modified Albumin (IMA) and Coagulation Parameters in Patients with SARS-CoV-2 Pneumonia

Analysis of Ischemia-Modified Albumin (IMA) and Coagulation Parameters in Patients with SARS-CoV-2 Pneumonia

The relationship between ischemia-modified albumin/albumin ratio levels and disease severity in COVID-19 patients

Plasma kallistatin levels in patients with COVID-19

Contact Info

Product

Resources

About